Search Results for: good news

Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA

mesenchymal cells

A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The “stem cells for heart disease” arena has also had a tough time. Here’s more news along these lines: BioCardia pauses enrollment in PhIII trial […]

Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA Read More »

Weekly stem cell reads: Google Bard AI issues, fat ball reprogramming, BrainStorm on ALS

stem cell research

It’s great finding stem cell videos on YouTube that are either excellent research talks or provide important information. I recently found one such video by Shiri Gur-Cohen, which I included below. Interesting data there and Shiri is such a compelling speaker. She also won The Niche image contest one year with a cool microscopy pic

Weekly stem cell reads: Google Bard AI issues, fat ball reprogramming, BrainStorm on ALS Read More »

Update on stem cells & cell therapy for COVID trials

cell therapy for COVID

From the beginning of the pandemic, I have been mostly skeptical about the idea of cell therapy for COVID including stem cell therapies. However, at the same time, I’ve closely followed the data, especially up until 2022. Now having just had a nasty bout with COVID myself for the first time this summer, I recently

Update on stem cells & cell therapy for COVID trials Read More »

Weekly reads: HIV from vampire facials, CAR-T, FDA warns Regenative Labs

vampire facials

Imagine regularly having someone rub your face all over with the equivalent of a small roller covered with spikes and doused with either your blood or someone else’s and you have what’s called vampire facials. There’s more news that this is a very bad idea. Vampire facials linked to more HIV cases “Vampire facials” promoted

Weekly reads: HIV from vampire facials, CAR-T, FDA warns Regenative Labs Read More »

Weekly reads: stem cell cost, trial death, HSCT for MS, Neuralink

So many things have gotten very expensive these days that it got me thinking this past week again about stem cell cost. For this reason, I’ve been running polls asking people what they’ve paid for stem cells and how many therapies they’ve gotten. Before jumping into our weekly reads, check out our informational post on

Weekly reads: stem cell cost, trial death, HSCT for MS, Neuralink Read More »

Weekly reads: reprogramming hearing loss, heart disease, eye drops, sickle cell

Regener-Eyes, eye drops

It’s mostly been a week of good and encouraging news in the regenerative medicine space including with gene therapies maybe with the exception of some eye drops warnings (more below). There’s realistic hope for an approved sickle cell disease soon. I also see some long-term positive news on hearing loss research. Hematopoietic stem cell transplant

Weekly reads: reprogramming hearing loss, heart disease, eye drops, sickle cell Read More »

Questions on National Academies in vitro gametogenesis (IVG) meeting sponsorship

in vitro gametogenesis, IVG

Research on in vitro gametogenesis or IVG is jumping ahead and such work could one day lead to new infertility treatments. In vitro gametogenesis is the process of producing gametes (sperm and eggs) from stem cells. Those powerful stem cells, called iPS cells, can be made from ordinary adult cells like skin or blood cells.

Questions on National Academies in vitro gametogenesis (IVG) meeting sponsorship Read More »

Weekly reads: FDA nod on new cell therapy, gray hair, pong-playing cells

It’s a big challenge to get a cell therapy approved by the FDA and if you look at my list of FDA-approved stem cell therapies, it’s not as long as we might hope. FDA OK on cell therapy from Gamida Cell For this reason, it was excellent news to see that the FDA approved a

Weekly reads: FDA nod on new cell therapy, gray hair, pong-playing cells Read More »

Weekly reads: Sarepta, epigenomics, FDA on eyedrops

Sarepa CEO interview.

The biotech Sarepta has had a complicated go of it with the FDA sometimes related to their Duchenne muscular dystrophy (DMD) gene therapy efforts. In late 2016 I wrote about how there was some controversy as the FDA approved the Sarepta drug eteplirsen (Exondys 51) also for DMD, going against an advisory panel that had

Weekly reads: Sarepta, epigenomics, FDA on eyedrops Read More »